Skip to main content
Premium Trial:

Request an Annual Quote

Diffinity Genomics Closes Series B Financing for Undisclosed Amount

Premium

Diffinity Genomics said this week that it has closed a Series B financing.

The privately held Rochester, NY-based company said it will use the funds primarily to commercialize new products, increase manufacturing capacity, and expand its sales team. However, a company spokesperson declined to disclose the financing amount.

The company's initial products, the Diffinity RapidTip and Diffinity RapidTip2, enable one-minute DNA purification from PCR solutions in a single step with a standard pipettor. Diffinity said that it is looking to add new RapidTip purification products to its portfolio for use in additional DNA purification applications.

New investors that contributed to the Series B round include Mass Med Angels and the Allyn Family Capital Fund.

Following the financing round, Diffinity appointed to its board of directors Donald Pogorzelski, former president of Genzyme Diagnostics and current vice chair of the New England Baptist Hospital's board of trustees; and Eric Allyn, an owner of medical device manufacturer Welch Allyn.

In September, Diffinity was awarded a pair of grants worth more than $200,000 from the National Human Genome Research Institute to further develop its nucleic acid purification technologies (PCR Insider, 9/15/2011).

Specifically, Lewis Rothberg, a professor of chemistry at the University of Rochester and chief technology officer at Diffinity, is principal investigator on the grants. Rothberg's lab developed the proprietary materials that Diffinity uses in its RapidTip. The company has a license to these technologies from the University of Rochester.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.